JP2019534251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019534251A5 JP2019534251A5 JP2019516622A JP2019516622A JP2019534251A5 JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5 JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019516622 A JP2019516622 A JP 2019516622A JP 2019534251 A5 JP2019534251 A5 JP 2019534251A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- taxane
- body surface
- surface area
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662401638P | 2016-09-29 | 2016-09-29 | |
| US62/401,638 | 2016-09-29 | ||
| PCT/US2017/053954 WO2018064299A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019534251A JP2019534251A (ja) | 2019-11-28 |
| JP2019534251A5 true JP2019534251A5 (https=) | 2020-11-12 |
Family
ID=60186360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019516622A Pending JP2019534251A (ja) | 2016-09-29 | 2017-09-28 | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190209701A1 (https=) |
| EP (1) | EP3518970A1 (https=) |
| JP (1) | JP2019534251A (https=) |
| KR (1) | KR20190061030A (https=) |
| CN (1) | CN109862917A (https=) |
| AU (1) | AU2017335839A1 (https=) |
| BR (1) | BR112019005815A2 (https=) |
| CA (1) | CA3038671A1 (https=) |
| IL (1) | IL265668A (https=) |
| MX (1) | MX2019003603A (https=) |
| TW (1) | TW201815419A (https=) |
| WO (1) | WO2018064299A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6896650B2 (ja) | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
| KR102739487B1 (ko) * | 2018-09-21 | 2024-12-10 | 제넨테크, 인크. | 3중-음성 유방암에 대한 진단 방법 |
| US20210348238A1 (en) * | 2018-10-16 | 2021-11-11 | Novartis Ag | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
| CN113194941A (zh) * | 2018-12-19 | 2021-07-30 | 基因泰克公司 | 使用包括akt抑制剂、紫杉烷和pd-l1抑制剂的组合疗法治疗乳腺癌 |
| MX2022015877A (es) * | 2020-06-16 | 2023-01-24 | Genentech Inc | Metodos y composiciones para tratar cancer de mama triple negativo. |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| US8146000B1 (en) | 2005-10-07 | 2012-03-27 | Goodwell Technologies, Inc. | Integrated transactional workflows distributed across multiple contact centers |
| HRP20110498T1 (hr) | 2005-10-07 | 2011-08-31 | Exelixis | Azetidini kao inhibitori mek za liječenje proliferativnih bolesti |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| JP6238459B2 (ja) * | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| DK2884979T3 (da) | 2012-08-17 | 2019-09-02 | Hoffmann La Roche | Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib |
| MA38085B1 (fr) | 2012-10-12 | 2018-11-30 | Exelixis Inc | Nouveau procédé pour la production de composés à utiliser dans le traitement du cancer |
| WO2015095404A2 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
| AU2014364606A1 (en) * | 2013-12-17 | 2016-07-07 | Genentech, Inc. | Combination therapy comprising OX40 binding agonists and PD-1 axis binding antagonists |
| JP6896650B2 (ja) * | 2015-06-17 | 2021-06-30 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及びタキサンを使用した局所進行性または転移性乳癌の治療方法 |
-
2017
- 2017-09-28 AU AU2017335839A patent/AU2017335839A1/en not_active Abandoned
- 2017-09-28 WO PCT/US2017/053954 patent/WO2018064299A1/en not_active Ceased
- 2017-09-28 TW TW106133384A patent/TW201815419A/zh unknown
- 2017-09-28 JP JP2019516622A patent/JP2019534251A/ja active Pending
- 2017-09-28 KR KR1020197011867A patent/KR20190061030A/ko not_active Ceased
- 2017-09-28 CA CA3038671A patent/CA3038671A1/en not_active Abandoned
- 2017-09-28 EP EP17791212.8A patent/EP3518970A1/en not_active Withdrawn
- 2017-09-28 CN CN201780065799.4A patent/CN109862917A/zh active Pending
- 2017-09-28 MX MX2019003603A patent/MX2019003603A/es unknown
- 2017-09-28 BR BR112019005815A patent/BR112019005815A2/pt not_active Application Discontinuation
-
2019
- 2019-03-27 IL IL265668A patent/IL265668A/en unknown
- 2019-03-27 US US16/366,411 patent/US20190209701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534251A5 (https=) | ||
| JP2018108086A5 (https=) | ||
| JP2018184417A5 (https=) | ||
| JP2019524820A5 (https=) | ||
| FI3849534T3 (fi) | Yhdistelmähoidot | |
| JP2017503820A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2012525853A5 (https=) | ||
| JP2015527318A5 (https=) | ||
| JP2018506550A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| IL300151A (en) | Combinations for cancer treatment | |
| JP2015529225A5 (https=) | ||
| JP2014515373A5 (https=) | ||
| JP2020521797A5 (https=) | ||
| JP2015530867A5 (https=) | ||
| JP2016503413A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| RU2015151454A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АФУКОЗИЛИРОВАННОГО АНТИТЕЛА К CD20 В СОЧЕТАНИИ С КОНЪЮГАТОМ АНТИТЕЛО К CD79b-ЛЕКАРСТВЕННОЕ СРЕДСТВО | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| JP2018530578A5 (https=) | ||
| JP2020517696A5 (https=) | ||
| JP2018529661A5 (https=) | ||
| JP2018522028A5 (https=) | ||
| RU2016128223A (ru) | Лечение вируса гриппа а h7n9 |